MX2023000630A - Inhibidor de rock, y método de preparacion para el mismo y uso del mismo. - Google Patents
Inhibidor de rock, y método de preparacion para el mismo y uso del mismo.Info
- Publication number
- MX2023000630A MX2023000630A MX2023000630A MX2023000630A MX2023000630A MX 2023000630 A MX2023000630 A MX 2023000630A MX 2023000630 A MX2023000630 A MX 2023000630A MX 2023000630 A MX2023000630 A MX 2023000630A MX 2023000630 A MX2023000630 A MX 2023000630A
- Authority
- MX
- Mexico
- Prior art keywords
- rock inhibitor
- preparation
- method therefor
- rock
- good
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 5
- 239000011435 rock Substances 0.000 title abstract 5
- 238000002360 preparation method Methods 0.000 title abstract 3
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 abstract 1
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Un inhibidor de ROCK representado por la fórmula (I), y un método de preparación para el mismo y un uso del mismo. El inhibidor de ROCK tiene una excelente actividad de inhibición de ROCK, particularmente muestra una buena inhibición selectiva sobre la cinasa ROCK2, tiene una buena seguridad y estabilidad metabólica, y es alta en biodisponibilidad. El método de preparación para el inhibidor de ROCK es simple, y el inhibidor de ROCK es fácil de purificar, y por lo tanto, tiene una buena perspectiva de aplicación. (Ver Fórmula I).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010676711 | 2020-07-14 | ||
CN202110040185 | 2021-01-11 | ||
PCT/CN2021/105263 WO2022012409A1 (zh) | 2020-07-14 | 2021-07-08 | 一种rock抑制剂及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023000630A true MX2023000630A (es) | 2023-03-15 |
Family
ID=79274325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023000630A MX2023000630A (es) | 2020-07-14 | 2021-07-08 | Inhibidor de rock, y método de preparacion para el mismo y uso del mismo. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230257376A1 (es) |
EP (1) | EP4155308A4 (es) |
JP (1) | JP2023534259A (es) |
KR (1) | KR20230038697A (es) |
CN (1) | CN113929678A (es) |
CA (1) | CA3184616A1 (es) |
MX (1) | MX2023000630A (es) |
TW (1) | TW202214628A (es) |
WO (1) | WO2022012409A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114573566B (zh) * | 2021-03-04 | 2023-05-30 | 杭州邦顺制药有限公司 | 选择性rock2激酶抑制剂 |
CN115894463A (zh) * | 2021-09-30 | 2023-04-04 | 武汉朗来科技发展有限公司 | 一种rock抑制剂的制备方法、其中间体及中间体的制备方法 |
TW202333672A (zh) * | 2022-01-13 | 2023-09-01 | 大陸商武漢朗來科技發展有限公司 | Rock抑制劑的鹽及鹽的晶型、組合物和藥物用途 |
CN114605325A (zh) * | 2022-03-23 | 2022-06-10 | 天方药业有限公司 | 一种医药中间体吡唑-4-乙酸盐酸盐的制备方法 |
CN116903594A (zh) * | 2022-04-20 | 2023-10-20 | 上海挚盟医药科技有限公司 | Rho相关蛋白激酶抑制剂及其制备和应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001025220A1 (en) * | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
KR100798579B1 (ko) * | 2001-03-31 | 2008-01-28 | 동화약품공업주식회사 | 신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물 |
EP1620437B1 (en) * | 2003-04-29 | 2009-06-17 | Pfizer Limited | 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension |
WO2008068171A1 (en) * | 2006-12-08 | 2008-06-12 | F. Hoffmann-La Roche Ag | Substituted pyrimidines and their use as jnk modulators |
JP5563466B2 (ja) * | 2007-10-19 | 2014-07-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ピペラジノ−ジヒドロチエノピリミジン誘導体 |
JP2012519732A (ja) * | 2009-03-09 | 2012-08-30 | サーフェイス ロジックス,インコーポレイティド | Rhoキナーゼ阻害剤 |
WO2015157556A1 (en) * | 2014-04-09 | 2015-10-15 | Kadmon Corporation, Llc | Treatment of gvhd |
US10729691B2 (en) * | 2015-06-26 | 2020-08-04 | Kadmon Corporation, Llc | Treatment of infectious diseases with glucose uptake inhibitors |
WO2016210330A1 (en) * | 2015-06-26 | 2016-12-29 | Kadmon Corporation, Llc | Glucose uptake inhibitors |
WO2018201006A1 (en) * | 2017-04-28 | 2018-11-01 | Kadmon Corporation, Llc | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors |
CN110582489B (zh) * | 2017-06-30 | 2023-10-27 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
JP2020525525A (ja) * | 2017-06-30 | 2020-08-27 | ベイジン タイド ファーマシューティカル カンパニー リミテッドBeijing Tide Pharmaceutical Co., Ltd. | Rho−関連プロテインキナーゼ阻害剤、rho−関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用 |
US10323023B2 (en) * | 2017-06-30 | 2019-06-18 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
WO2019045824A1 (en) * | 2017-09-01 | 2019-03-07 | Kadmon Corporation, Llc | ALPHA PROPELLER PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO |
CN112969694B (zh) * | 2018-11-09 | 2023-06-13 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其用途 |
CA3130478A1 (en) * | 2019-03-13 | 2020-09-17 | Voronoi Co., Ltd. | Heteroaryl derivatives, and pharmaceutical composition comprising the same as active ingredient |
US11608319B2 (en) * | 2019-12-31 | 2023-03-21 | Industrial Technology Research Institute | Beta-amino acid derivative, kinase inhibitor and pharmaceutical composition containing the same, and method for performing an in vivo related application that benefits from the inhibition of a kinase |
-
2021
- 2021-07-08 MX MX2023000630A patent/MX2023000630A/es unknown
- 2021-07-08 WO PCT/CN2021/105263 patent/WO2022012409A1/zh unknown
- 2021-07-08 US US18/005,165 patent/US20230257376A1/en active Pending
- 2021-07-08 JP JP2023502738A patent/JP2023534259A/ja active Pending
- 2021-07-08 KR KR1020237000774A patent/KR20230038697A/ko active Search and Examination
- 2021-07-08 CN CN202110776971.5A patent/CN113929678A/zh active Pending
- 2021-07-08 EP EP21842081.8A patent/EP4155308A4/en active Pending
- 2021-07-08 CA CA3184616A patent/CA3184616A1/en active Pending
- 2021-07-14 TW TW110125960A patent/TW202214628A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA3184616A1 (en) | 2022-01-20 |
TW202214628A (zh) | 2022-04-16 |
JP2023534259A (ja) | 2023-08-08 |
EP4155308A4 (en) | 2024-04-17 |
EP4155308A1 (en) | 2023-03-29 |
KR20230038697A (ko) | 2023-03-21 |
AU2021309876A1 (en) | 2023-02-23 |
CN113929678A (zh) | 2022-01-14 |
US20230257376A1 (en) | 2023-08-17 |
WO2022012409A1 (zh) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023000630A (es) | Inhibidor de rock, y método de preparacion para el mismo y uso del mismo. | |
MX2020000710A (es) | Compuesto de aril-fósforo-oxígeno como inhibidor de la cinasa del egfr. | |
GEP201606532B (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
MX2022005858A (es) | Inhibidor de la rock y metodo de preparacion para el mismo y uso del mismo. | |
MX344025B (es) | Inhibidores de proteínas quinasas. | |
CY1118088T1 (el) | Παραγωγο πουρινονης ως εκλεκτικος αναστολεας βτκ κινασης | |
NZ733899A (en) | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | |
TN2018000262A1 (en) | Substituted piperidine compound and use there of. | |
MY141196A (en) | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | |
NO20076054L (no) | Imidiazo - og triazolopyridiner som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase type I | |
CA2875877C (en) | Syk inhibitors | |
PH12015502284A1 (en) | Protein kinase inhibitors | |
MX371167B (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta). | |
NO20076055L (no) | Imidazo- og triazolopyridiner som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase type I | |
MX2012000766A (es) | Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina. | |
MX2010008686A (es) | Derivado de pirrolopirimidina como inhibidor de fosfatidilinositol 3-quinasa y uso del mismo. | |
UA92324C2 (en) | Novel 2-substituted d-homo-estra-1,3,5(10)-trienes as inhibitors of 17я-hydroxysteroid dehydrogenase type 1 | |
IN2014DN07509A (es) | ||
UA105527C2 (uk) | Сполука-інгібітор матриптази для лікування раку | |
MX2017005422A (es) | Inhibidores de histona desacetilasa y sus usos en terapia. | |
MX2023009037A (es) | Compuesto de pirimidopirano. | |
IN2015DN03235A (es) | ||
MX2022005201A (es) | Formulaciones de naftalimida dimerica. | |
MX2021013981A (es) | Inhibidores de la cinasa aurora y usos de los mismos. | |
MX2019005723A (es) | Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo. |